Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8821348 | Clinical Imaging | 2018 | 24 Pages |
Abstract
BRCA mutation carriers demonstrated lower levels of breast parenchymal enhancement and amount of fibroglandular tissue than age-matched non-carriers. These differences are probably influenced by hormonal status, as well as highlight different risks in distinctive subgroups of breast cancer (hormone-enriched, mutation-associated defective DNA damage repair), affecting considerations of preventive medical treatment. Differences in the indications for imaging between the carrier and non-carrier groups (screening for mutations and breast cancer evaluation, respectively) probably accounted for the higher rate of BI-RADS 3 in the control group.
Related Topics
Health Sciences
Medicine and Dentistry
Radiology and Imaging
Authors
Ahuva Grubstein, Yael Rapson, Oshra Benzaquen, Shira Rozenblatt, Itay Gadiel, Eli Atar, Rinat Yerushalmi, Matan J. Cohen,